Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations

Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations

To review the clinical evidence on abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology. An expert panel of rheumatologists objectively summarized the evidence on the mechanism of action, practicalities, effectiveness and safety of abatacept, and...

Full description

Saved in:
Bibliographic Details
Published in:Reumatología clinica (Barcelona) Vol. 9; no. 1; pp. 5 - 17
Main Authors: Martín Mola, Emilio, Balsa, Alejandro, Martínez Taboada, Víctor, Sanmartí, Raimon, Marenco, José Luis, Navarro Sarabia, Federico, Gómez-Reino, Juan, Álvaro-Gracia, José María, Román Ivorra, José Andrés, Lojo, Leticia, Plasencia, Chamaida, Carmona, Loreto
Format: Journal Article
Language:English
Published: Elsevier España, S.L.U 01-01-2013
Subjects:
Abatacept
CTLA-4-Ig
Evidence-based practice
Práctica basada en evidencias
Abatacept
CTLA-4-Ig
Práctica basada en evidencias
Evidence-based practice
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract To review the clinical evidence on abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology. An expert panel of rheumatologists objectively summarized the evidence on the mechanism of action, practicalities, effectiveness and safety of abatacept, and formulated recommendations following a literature review. The level of evidence and degree of recommendation was established. The document presents 21 statements focused on evidence or recommendations on abatacept (14 evidence summaries and 9 recommendations). The level of evidence was 2b or higher according to the Oxford Centre for Evidence-Based Medicine scale on 14 occasions. The degree of the recommendation was A in two recommendations, C in one, and D in the rest. It was considered important to make recommendations on aspects with lower levels of evidence. This is a practical document to supplement the summary of product characteristics. Revisar la evidencia clínica sobre abatacept y emitir recomendaciones con objeto de aclarar su uso en Reumatología. Un panel de expertos reumatólogos resumió de forma objetiva las pruebas existentes sobre el mecanismo de acción, modo de uso, eficacia y seguridad de abatacept y emitió recomendaciones de uso en situaciones concretas, previa revisión de la bibliografía. Se estableció el nivel de evidencia de las pruebas y el grado de apoyo de dichos datos a las recomendaciones emitidas. El documento presenta 21 enunciados resumen de la evidencia encontrada o recomendaciones sobre abatacept (14 enunciados y 9 recomendaciones). El nivel de evidencia es superior a 2b según la escala de Oxford del Centro de Medicina Basada en la Evidencia en 14 ocasiones. El grado de apoyo de las recomendaciones es A en 2 recomendaciones, C en una y D en el resto. Se consideró importante realizar recomendaciones precisamente en los aspectos con menor grado de evidencia. Se trata de un documento práctico como complemento a la información en ficha técnica.
AbstractList To review the clinical evidence on abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology. An expert panel of rheumatologists objectively summarized the evidence on the mechanism of action, practicalities, effectiveness and safety of abatacept, and formulated recommendations following a literature review. The level of evidence and degree of recommendation was established. The document presents 21 statements focused on evidence or recommendations on abatacept (14 evidence summaries and 9 recommendations). The level of evidence was 2b or higher according to the Oxford Centre for Evidence-Based Medicine scale on 14 occasions. The degree of the recommendation was A in two recommendations, C in one, and D in the rest. It was considered important to make recommendations on aspects with lower levels of evidence. This is a practical document to supplement the summary of product characteristics. Revisar la evidencia clínica sobre abatacept y emitir recomendaciones con objeto de aclarar su uso en Reumatología. Un panel de expertos reumatólogos resumió de forma objetiva las pruebas existentes sobre el mecanismo de acción, modo de uso, eficacia y seguridad de abatacept y emitió recomendaciones de uso en situaciones concretas, previa revisión de la bibliografía. Se estableció el nivel de evidencia de las pruebas y el grado de apoyo de dichos datos a las recomendaciones emitidas. El documento presenta 21 enunciados resumen de la evidencia encontrada o recomendaciones sobre abatacept (14 enunciados y 9 recomendaciones). El nivel de evidencia es superior a 2b según la escala de Oxford del Centro de Medicina Basada en la Evidencia en 14 ocasiones. El grado de apoyo de las recomendaciones es A en 2 recomendaciones, C en una y D en el resto. Se consideró importante realizar recomendaciones precisamente en los aspectos con menor grado de evidencia. Se trata de un documento práctico como complemento a la información en ficha técnica.
Author Navarro Sarabia, Federico
Sanmartí, Raimon
Martínez Taboada, Víctor
Marenco, José Luis
Lojo, Leticia
Román Ivorra, José Andrés
Martín Mola, Emilio
Gómez-Reino, Juan
Carmona, Loreto
Álvaro-Gracia, José María
Balsa, Alejandro
Plasencia, Chamaida
Author_xml – sequence: 1
  givenname: Emilio
  surname: Martín Mola
  fullname: Martín Mola, Emilio
  email: emartinmola.hulp@salud.madrid.org
  organization: Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
– sequence: 2
  givenname: Alejandro
  surname: Balsa
  fullname: Balsa, Alejandro
  organization: Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
– sequence: 3
  givenname: Víctor
  surname: Martínez Taboada
  fullname: Martínez Taboada, Víctor
  organization: Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
– sequence: 4
  givenname: Raimon
  surname: Sanmartí
  fullname: Sanmartí, Raimon
  organization: Servicio de Reumatología, Hospital Clínic i Provincial, Barcelona, Spain
– sequence: 5
  givenname: José Luis
  surname: Marenco
  fullname: Marenco, José Luis
  organization: Servicio de Reumatología, Hospital Universitario Virgen de Valme, Sevilla, Spain
– sequence: 6
  givenname: Federico
  surname: Navarro Sarabia
  fullname: Navarro Sarabia, Federico
  organization: Servicio de Reumatología, Hospital Universitario Virgen Macarena, Sevilla, Spain
– sequence: 7
  givenname: Juan
  surname: Gómez-Reino
  fullname: Gómez-Reino, Juan
  organization: Servicio de Reumatología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
– sequence: 8
  givenname: José María
  surname: Álvaro-Gracia
  fullname: Álvaro-Gracia, José María
  organization: Servicio de Reumatología, Hospital Universitario IIS Princesa, Madrid, Spain
– sequence: 9
  givenname: José Andrés
  surname: Román Ivorra
  fullname: Román Ivorra, José Andrés
  organization: Servicio de Reumatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
– sequence: 10
  givenname: Leticia
  surname: Lojo
  fullname: Lojo, Leticia
  organization: Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
– sequence: 11
  givenname: Chamaida
  surname: Plasencia
  fullname: Plasencia, Chamaida
  organization: Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
– sequence: 12
  givenname: Loreto
  surname: Carmona
  fullname: Carmona, Loreto
  organization: Servicio de Reumatología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
BookMark eNp9kM1qwzAQhEVJoWmaN-hBL2B3ZSuS3UMhhPSPQCE0ZyHLK6JQy0FSU_r2tUkPPXUvO5cZZr5rMvG9R0JuGeQMmLg75AE_O415AazIQeYA9QWZFkyW2ULycvJHX5F5jAcYrioWtZBT8rpsdNIGj4nuIlLn6XY_xqXetXQZ0j645OI9XZ9ci94g3eLJ4RfVvh2k6bsOfauT6328IZdWf0Sc__4Z2T2u31fP2ebt6WW13GRm6AFZw2VTCysZsxxqI4VmILgVbSNFVXCwtdSN5rqSlaiFMNpWGmwJWvASYWHLGeHnXBP6GANadQyu0-FbMVAjEnVQZyRqRKJAqgHJYHs423DoNmwIKho3TmpdQJNU27v_A34A24ltQg
CitedBy_id crossref_primary_10_1292_jvms_16_0583
Cites_doi 10.3899/jrheum.080813
10.2217/ijr.10.52
10.1007/s00296-009-1041-1
10.1136/ard.2008.097527
10.1136/ard.2006.055111
10.1136/ard.2010.132134
10.1136/ard.2008.099218
10.1097/RHU.0b013e3181f4cd92
10.1056/NEJMoa035075
10.1093/rheumatology/ker289
10.1111/j.0105-2896.2005.00242.x
10.1136/ard.2010.139345
10.1172/JCI118146
10.2217/ijr.11.1
10.1592/phco.31.1.39
10.1503/cmaj.091391
10.3310/hta15140
10.1136/ard.2010.146852
10.1016/j.jbspin.2008.12.007
10.1136/ard.2007.080002
10.1073/pnas.220423597
10.1016/j.clim.2007.08.019
10.1111/j.1742-7843.2009.00375.x
10.1002/art.30463
10.1056/NEJMoa050524
10.1136/ard.2008.101121
10.1136/ard.2010.145268
10.1186/ar2174
10.1186/ar2404
10.1097/BOR.0b013e328329f84f
10.1093/rheumatology/keq287
10.1136/ard.2009.119727
10.1016/j.jval.2010.10.008
10.7326/0003-4819-144-12-200606200-00003
10.1212/01.wnl.0000325915.00112.61
10.1007/s10067-009-1363-0
10.1136/ard.2008.091876
10.1186/ar2984
10.1136/annrheumdis-2011-200316
10.1002/art.27431
10.1002/art.21201
10.1002/art.22070
10.1016/j.autrev.2008.07.035
10.1002/art.22750
10.1136/ard.2010.140129
10.1007/s10875-011-9527-5
10.1136/ard.2007.080713
10.1016/j.semarthrit.2009.12.002
10.1093/rheumatology/kep354
10.1136/ard.2007.085084
10.1136/annrheumdis-2011-200344
10.1016/j.reuma.2011.05.002
ContentType Journal Article
Copyright 2012 Elsevier España, S.L.
Copyright_xml – notice: 2012 Elsevier España, S.L.
DBID AAYXX
CITATION
DOI 10.1016/j.reumae.2012.07.009
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate El uso de abatacept en artritis reumatoide: revisión de la evidencia y recomendaciones
EISSN 2173-5743
EndPage 17
ExternalDocumentID 10_1016_j_reumae_2012_07_009
S217357431200127X
GroupedDBID --K
--M
.1-
.FO
.~1
0R~
1P~
1~.
1~5
4.4
457
4G.
53G
65R
7-5
8P~
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
ABBQC
ABLVK
ABMAC
ABMZM
ABXDB
ACDAQ
ACGFS
ACRLP
ADBBV
ADCUG
ADEZE
AEBSH
AEKER
AEVXI
AFCTW
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
BNPGV
EBS
EFJIC
EFLBG
EJD
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
KOM
LCYCR
M41
MO0
O-L
O9-
OAUVE
OI0
OV-
P-8
P-9
PC.
Q38
RIG
ROL
SDF
SPCBC
SSH
SSZ
T5K
Z5R
~G-
AAQFI
AAXKI
AAXUO
AAYXX
AFJKZ
AFOST
CITATION
SHL
ID FETCH-LOGICAL-c2170-b47b96f711f409c76a1064f6db768240f97aba4a8786966caf8a0f30a643e05f3
ISSN 2173-5743
IngestDate Thu Sep 26 17:18:55 EDT 2024
Fri Feb 23 02:38:25 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Abatacept
CTLA-4-Ig
Práctica basada en evidencias
Evidence-based practice
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2170-b47b96f711f409c76a1064f6db768240f97aba4a8786966caf8a0f30a643e05f3
PageCount 13
ParticipantIDs crossref_primary_10_1016_j_reumae_2012_07_009
elsevier_sciencedirect_doi_10_1016_j_reumae_2012_07_009
PublicationCentury 2000
PublicationDate January-February 2013
2013-1-00
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – month: 01
  year: 2013
  text: January-February 2013
PublicationDecade 2010
PublicationTitle Reumatología clinica (Barcelona)
PublicationYear 2013
Publisher Elsevier España, S.L.U
Publisher_xml – name: Elsevier España, S.L.U
References Keir, Sharpe (bib0065) 2005; 204
Yazici, McMorris, Darkow, Rosenblatt (bib0110) 2009; 27
Genant, Peterfy, Westhovens, Becker, Vratsanos, Zhou (bib0455) 2009; 68
Hadjinicolaou, Nisar, Bhagat, Parfrey, Chilvers, Ostor (bib0375) 2011; 50
Harrold, Reed, Rosenblatt, Mody, Reed, Greenberg (bib0270) 2010; 62
Kuhns, Epshteyn, Sobel, Allison (bib0070) 2000; 97
Westhovens, Kremer, Emery, Russell, Li, Aranda (bib0210) 2009; 68
Schiff (bib0225) 2011; 50
Bergman, Hochberg, Boers, Wintfeld, Kielhorn, Jansen (bib0010) 2010; 39
Donato, Hines, L’Italien, Bourgault, Zabransky, Fanti (bib0280) 2009; 68
Genovese, Becker, Schiff, Luggen, Sherrer, Kremer (bib0160) 2005; 353
Schiff, Keiserman, Codding, Songcharoen, Berman, Nayiager (bib0190) 2011; 70
Keystone (bib0180) 2009; 21
Roos, Chilvers, Ostor (bib0450) 2007; 34
Mahajan, Hooker, Maher, Brown, Reimold (bib0350) 2010; 16
Furst, Keystone, Braun, Breedveld, Burmester, De Benedetti (bib0445) 2011; 70
Westhovens, Kremer, Moreland, Emery, Russell, Li (bib0205) 2009; 36
Viglietta, Bourcier, Buckle, Healy, Weiner, Hafler (bib0395) 2008; 71
Salliot, Finckh, Katchamart, Lu, Sun, Bombardier (bib0300) 2011; 70
Choy (bib0055) 2009; 27
Weinblatt, Combe, Birbara, Covucci, Li, Becker (bib0320) 2006; 54
Simon, Askling, Lacaille, Franklin, Wolfe, Covucci (bib0325) 2010; 12
Smitten, Qi, Simon, Becker (bib0385) 2008; 58
Schimmel, Yazici (bib0440) 2009; 27
Westhovens, Robles, Ximenes, Nayiager, Wollenhaupt, Durez (bib0170) 2009; 68
Genovese, Covarrubias, Leon, Mysler, Keiserman, Valente (bib0125) 2011; 63
Genant, Peterfy, Westhovens, Becker, Aranda, Vratsanos (bib0185) 2008; 67
Phillips, Ball, Sackett, Badenoch, Straus, Haynes (bib0035) 2011
Kremer, Genant, Moreland, Russell, Emery, Abud-Mendoza (bib0150) 2006; 144
Gottenberg, Ravaud, Bardin, Cacoub, Cantagrel, Combe (bib0260) 2010; 69
Kremer, Russell, Emery, Abud-Mendoza, Szechinski, Westhovens (bib0200) 2011; 70
Davis, Nadler, Stetsko, Suchard (bib0075) 2008; 126
Singh, Christensen, Wells, Suarez-Almazor, Buchbinder, Lopez-Olivo (bib0005) 2009; 181
Schiff, Kaell, Tay, Vratsanos, Bahrt (bib0410) 2007; 66
Weinblatt, Schiff, Goldman, Kremer, Luggen, Li (bib0425) 2007; 66
Gómez-Reino, Loza Santamaría, Andreu, Balsa, Batlle, Cañete (bib0310) 2011; 07
Kremer, Russell, Westhovens, Teng, Rosenblatt, Emery (bib0240) 2010; 62
Simon, Smitten, Franklin, Askling, Lacaille, Wolfe (bib0370) 2009; 68
Gottenberg, Ravaud, Bardin, Cantagrel, Combe, Dougados (bib0285) 2011; 70
Mathieu, Motreff, Dubost, Malochet-Guinamand, Ristori, Soubrier (bib0430) 2010; 69
Schiff, Pritchard, Huffstutter, Rodriguez-Valverde, Durez, Zhou (bib0165) 2009; 68
Genovese, Schiff, Luggen, Le Bars, Becker, Aranda (bib0230) 2010; 69
Vieira, Callado, Vieira (bib0355) 2010; 30
Buch, Boyle, Rosengren, Saleem, Reece, Rhodes (bib0090) 2009; 68
Gibofsky, Kremer, Moniz Reed, Reed, Vratsanos, Greenberg (bib0275) 2009; 68
Maxwell, Singh (bib0030) 2009
Buch, Saleem, Das, Bryer, Emery (bib0290) 2010; 69
Smitten, Simon, Hochberg, Suissa (bib0365) 2008; 10
Ribeiro, Guedes, Moraes, Saad, Calich, Aikawa (bib0420) 2011; 70
Falgarone, Semerano, Rulle, Boissier (bib0050) 2009; 76
Tay, Leon, Vratsanos, Raymond, Corbo (bib0405) 2007; 9
Devine, Alfonso-Cristancho, Sullivan (bib0015) 2011; 31
Rao, Bowden, Nyfort-Hansen (bib0380) 2011; 16
Davis, Abraham, Xu, Nadler, Suchard (bib0105) 2007; 34
Alvarez-Quiroga, Abud-Mendoza, Doniz-Padilla, Juarez-Reyes, Monsivais-Urenda, Baranda (bib0095) 2011; 31
Li, Wells, Westhovens, Emery, Becker, Tugwell (bib0245) 2011; 14
Singh, Wells, Christensen, Tanjong Ghogomu, Maxwell, Macdonald (bib0020) 2011; 2
Kaine, Gladstein, Strusberg, Robles, Louw, Gujrathi (bib0130) 2012; 71
Solomon (bib0045) 2010; 68
Schiff, Keiserman, Codding, Songcharoen, Berman, Nayiager (bib0155) 2008; 67
Bristol-Myers Squibb Pharma (bib0025) 2007
Korhonen, Moilanen (bib0040) 2009; 104
Schiff, Poncet, Bars (bib0250) 2010; 5
Weisman, Durez, Hallegua, Aranda, Becker, Nuamah (bib0080) 2006; 33
Smitten, Becker, Qi, Kelly, Aranda (bib0330) 2010; 69
Kremer, Dougados, Emery, Durez, Sibilia, Shergy (bib0145) 2005; 52
Kushnir, Ashurova, Shriky, Swearingen, Yazici (bib0115) 2010; 69
Zisopoulos, Eustathiou, Dimitroulas (bib0360) 2010; 69
Schiff, Bessette (bib0220) 2010; 29
Smitten, Covucci, Simon (bib0335) 2008; 67
Hochberg, Westhovens, Aranda, Kelly, Khan, Qi (bib0400) 2010; 62
Axmann, Herman, Zaiss, Franz, Polzer, Zwerina (bib0100) 2008; 67
Peterfy, Wu, Szechinski, DiCarlo, Lu, Genovese (bib0175) 2011; 6
Schiff, Saewert, Bahrt, Genovese (bib0415) 2007; 57
Weinblatt, Combe, Covucci, Aranda, Becker, Keystone (bib0315) 2006; 54
Kremer, Westhovens, Leon, Di Giorgio, Alten, Steinfeld (bib0140) 2003; 349
Smitten, Westhovens, Hochberg, Torbeyns, Becker, Aranda (bib0340) 2010; 69
Ruperto, Lovell, Quartier, Paz, Rubio-Perez, Silva (bib0390) 2010; 62
Emery, Kremer, Moreland, Russell, Li, Aranda (bib0215) 2008; 47
Wells, Li, Tugwell (bib0235) 2010; 69
Simons, Trivedi, Rosenblatt (bib0120) 2009; 68
Bigbee, Gonchoroff, Vratsanos, Nadler, Haggerty, Flynn (bib0345) 2007; 56
Leffers, Ostergaard, Glintborg, Krogh, Foged, Tarp (bib0265) 2011; 70
Knoerzer, Karr, Schwartz, Mengle-Gaw (bib0085) 1995; 96
Scarpato, Antivalle, Favalli, Nacci, Frigelli, Bartoli (bib0135) 2010; 49
Mathieu, Szymanski, Dubost, Mrozek, Marceau, Ristori (bib0435) 2010; 62
Bathon, Robles, Ximenes, Nayiager, Wollenhaupt, Durez (bib0195) 2011; 70
Fiocco, Sfriso, Oliviero, Pagnin, Scagliori, Campana (bib0060) 2008; 8
Gottenberg, Flipo, Cantagrel, Schaeverbeke, Houvenagel, Legrand (bib0255) 2010; 69
Malottki, Barton, Tsourapas, Uthman, Liu, Routh (bib0295) 2011; 15
Lopez-Olivo, Shaw, Suarez-Almazor (bib0305) 2010; 62
Kremer (10.1016/j.reumae.2012.07.009_bib0200) 2011; 70
Hadjinicolaou (10.1016/j.reumae.2012.07.009_bib0375) 2011; 50
Genant (10.1016/j.reumae.2012.07.009_bib0185) 2008; 67
Genovese (10.1016/j.reumae.2012.07.009_bib0125) 2011; 63
Devine (10.1016/j.reumae.2012.07.009_bib0015) 2011; 31
Leffers (10.1016/j.reumae.2012.07.009_bib0265) 2011; 70
Buch (10.1016/j.reumae.2012.07.009_bib0290) 2010; 69
Alvarez-Quiroga (10.1016/j.reumae.2012.07.009_bib0095) 2011; 31
Harrold (10.1016/j.reumae.2012.07.009_bib0270) 2010; 62
Smitten (10.1016/j.reumae.2012.07.009_bib0385) 2008; 58
Viglietta (10.1016/j.reumae.2012.07.009_bib0395) 2008; 71
Solomon (10.1016/j.reumae.2012.07.009_bib0045) 2010; 68
Rao (10.1016/j.reumae.2012.07.009_bib0380) 2011; 16
Schiff (10.1016/j.reumae.2012.07.009_bib0165) 2009; 68
Genovese (10.1016/j.reumae.2012.07.009_bib0230) 2010; 69
Weinblatt (10.1016/j.reumae.2012.07.009_bib0425) 2007; 66
Genant (10.1016/j.reumae.2012.07.009_bib0455) 2009; 68
Korhonen (10.1016/j.reumae.2012.07.009_bib0040) 2009; 104
Kremer (10.1016/j.reumae.2012.07.009_bib0150) 2006; 144
Kaine (10.1016/j.reumae.2012.07.009_bib0130) 2012; 71
Schiff (10.1016/j.reumae.2012.07.009_bib0225) 2011; 50
Simon (10.1016/j.reumae.2012.07.009_bib0370) 2009; 68
Schiff (10.1016/j.reumae.2012.07.009_bib0250) 2010; 5
Kuhns (10.1016/j.reumae.2012.07.009_bib0070) 2000; 97
Buch (10.1016/j.reumae.2012.07.009_bib0090) 2009; 68
Malottki (10.1016/j.reumae.2012.07.009_bib0295) 2011; 15
Roos (10.1016/j.reumae.2012.07.009_bib0450) 2007; 34
Westhovens (10.1016/j.reumae.2012.07.009_bib0210) 2009; 68
Ribeiro (10.1016/j.reumae.2012.07.009_bib0420) 2011; 70
Singh (10.1016/j.reumae.2012.07.009_bib0005) 2009; 181
Tay (10.1016/j.reumae.2012.07.009_bib0405) 2007; 9
Schimmel (10.1016/j.reumae.2012.07.009_bib0440) 2009; 27
Ruperto (10.1016/j.reumae.2012.07.009_bib0390) 2010; 62
Axmann (10.1016/j.reumae.2012.07.009_bib0100) 2008; 67
Schiff (10.1016/j.reumae.2012.07.009_bib0220) 2010; 29
Schiff (10.1016/j.reumae.2012.07.009_bib0410) 2007; 66
Choy (10.1016/j.reumae.2012.07.009_bib0055) 2009; 27
Peterfy (10.1016/j.reumae.2012.07.009_bib0175) 2011; 6
Mahajan (10.1016/j.reumae.2012.07.009_bib0350) 2010; 16
Maxwell (10.1016/j.reumae.2012.07.009_bib0030) 2009
Schiff (10.1016/j.reumae.2012.07.009_bib0155) 2008; 67
Singh (10.1016/j.reumae.2012.07.009_bib0020) 2011; 2
Bergman (10.1016/j.reumae.2012.07.009_bib0010) 2010; 39
Keir (10.1016/j.reumae.2012.07.009_bib0065) 2005; 204
Kremer (10.1016/j.reumae.2012.07.009_bib0240) 2010; 62
Mathieu (10.1016/j.reumae.2012.07.009_bib0430) 2010; 69
Wells (10.1016/j.reumae.2012.07.009_bib0235) 2010; 69
Bristol-Myers Squibb Pharma (10.1016/j.reumae.2012.07.009_bib0025) 2007
Emery (10.1016/j.reumae.2012.07.009_bib0215) 2008; 47
Salliot (10.1016/j.reumae.2012.07.009_bib0300) 2011; 70
Fiocco (10.1016/j.reumae.2012.07.009_bib0060) 2008; 8
Kushnir (10.1016/j.reumae.2012.07.009_bib0115) 2010; 69
Gottenberg (10.1016/j.reumae.2012.07.009_bib0255) 2010; 69
Donato (10.1016/j.reumae.2012.07.009_bib0280) 2009; 68
Simon (10.1016/j.reumae.2012.07.009_bib0325) 2010; 12
Phillips (10.1016/j.reumae.2012.07.009_bib0035) 2011
Schiff (10.1016/j.reumae.2012.07.009_bib0190) 2011; 70
Furst (10.1016/j.reumae.2012.07.009_bib0445) 2011; 70
Gómez-Reino (10.1016/j.reumae.2012.07.009_bib0310) 2011; 07
Kremer (10.1016/j.reumae.2012.07.009_bib0145) 2005; 52
Smitten (10.1016/j.reumae.2012.07.009_bib0335) 2008; 67
Falgarone (10.1016/j.reumae.2012.07.009_bib0050) 2009; 76
Bathon (10.1016/j.reumae.2012.07.009_bib0195) 2011; 70
Kremer (10.1016/j.reumae.2012.07.009_bib0140) 2003; 349
Scarpato (10.1016/j.reumae.2012.07.009_bib0135) 2010; 49
Weinblatt (10.1016/j.reumae.2012.07.009_bib0315) 2006; 54
Westhovens (10.1016/j.reumae.2012.07.009_bib0170) 2009; 68
Davis (10.1016/j.reumae.2012.07.009_bib0075) 2008; 126
Genovese (10.1016/j.reumae.2012.07.009_bib0160) 2005; 353
Hochberg (10.1016/j.reumae.2012.07.009_bib0400) 2010; 62
Gibofsky (10.1016/j.reumae.2012.07.009_bib0275) 2009; 68
Gottenberg (10.1016/j.reumae.2012.07.009_bib0260) 2010; 69
Schiff (10.1016/j.reumae.2012.07.009_bib0415) 2007; 57
Vieira (10.1016/j.reumae.2012.07.009_bib0355) 2010; 30
Bigbee (10.1016/j.reumae.2012.07.009_bib0345) 2007; 56
Zisopoulos (10.1016/j.reumae.2012.07.009_bib0360) 2010; 69
Westhovens (10.1016/j.reumae.2012.07.009_bib0205) 2009; 36
Li (10.1016/j.reumae.2012.07.009_bib0245) 2011; 14
Weinblatt (10.1016/j.reumae.2012.07.009_bib0320) 2006; 54
Knoerzer (10.1016/j.reumae.2012.07.009_bib0085) 1995; 96
Yazici (10.1016/j.reumae.2012.07.009_bib0110) 2009; 27
Smitten (10.1016/j.reumae.2012.07.009_bib0340) 2010; 69
Lopez-Olivo (10.1016/j.reumae.2012.07.009_bib0305) 2010; 62
Smitten (10.1016/j.reumae.2012.07.009_bib0365) 2008; 10
Davis (10.1016/j.reumae.2012.07.009_bib0105) 2007; 34
Gottenberg (10.1016/j.reumae.2012.07.009_bib0285) 2011; 70
Simons (10.1016/j.reumae.2012.07.009_bib0120) 2009; 68
Keystone (10.1016/j.reumae.2012.07.009_bib0180) 2009; 21
Mathieu (10.1016/j.reumae.2012.07.009_bib0435) 2010; 62
Smitten (10.1016/j.reumae.2012.07.009_bib0330) 2010; 69
Weisman (10.1016/j.reumae.2012.07.009_bib0080) 2006; 33
References_xml – volume: 70
  start-page: 1216
  year: 2011
  end-page: 1222
  ident: bib0265
  article-title: Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Tarp
– volume: 16
  start-page: 69
  year: 2011
  ident: bib0380
  article-title: Pulmonary toxicity of biological anti-inflammatory agents—a systematic review
  publication-title: Respirology
  contributor:
    fullname: Nyfort-Hansen
– volume: 62
  start-page: S164
  year: 2010
  end-page: S165
  ident: bib0400
  article-title: Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment
  publication-title: Arthritis Rheum
  contributor:
    fullname: Qi
– volume: 71
  start-page: 38
  year: 2012
  end-page: 44
  ident: bib0130
  article-title: Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Gujrathi
– volume: 70
  start-page: 2003
  year: 2011
  end-page: 2007
  ident: bib0190
  article-title: Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Nayiager
– volume: 27
  start-page: 510
  year: 2009
  end-page: 518
  ident: bib0055
  article-title: Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Choy
– volume: 69
  start-page: 388
  year: 2010
  ident: bib0430
  article-title: Assessment of arterial stiffness after 24 weeks of abatacept therapy in 17 patients with rheumatoid arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Soubrier
– volume: 29
  start-page: 583
  year: 2010
  end-page: 591
  ident: bib0220
  article-title: Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis
  publication-title: Clin Rheumatol
  contributor:
    fullname: Bessette
– volume: 70
  start-page: 1826
  year: 2011
  end-page: 1830
  ident: bib0200
  article-title: Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Westhovens
– volume: 12
  start-page: R67
  year: 2010
  ident: bib0325
  article-title: Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
  publication-title: Arthritis Res Ther
  contributor:
    fullname: Covucci
– start-page: CD007277
  year: 2009
  ident: bib0030
  article-title: Abatacept for rheumatoid arthritis
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Singh
– volume: 67
  start-page: 338
  year: 2008
  ident: bib0335
  article-title: Descriptive analysis of serious infections, hospitalized infections and malignancies over time in the abatacept clinical development program: a safety update with 10,000 person-years of exposure
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Simon
– volume: 21
  start-page: 231
  year: 2009
  end-page: 237
  ident: bib0180
  article-title: Recent concepts in the inhibition of radiographic progression with biologics
  publication-title: Curr Opin Rheumatol
  contributor:
    fullname: Keystone
– volume: 69
  start-page: 200
  year: 2010
  ident: bib0360
  article-title: Biological agents in inactive HBsAg carriers with inflammatory arthritis: a role of prophylactic antiviral treatment
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Dimitroulas
– volume: 50
  start-page: 2297
  year: 2011
  end-page: 2305
  ident: bib0375
  article-title: Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review
  publication-title: Rheumatology (Oxford)
  contributor:
    fullname: Ostor
– volume: 34
  start-page: 2204
  year: 2007
  end-page: 2210
  ident: bib0105
  article-title: Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity
  publication-title: J Rheumatol
  contributor:
    fullname: Suchard
– volume: 68
  start-page: 440
  year: 2009
  ident: bib0455
  article-title: Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Zhou
– volume: 66
  start-page: 228
  year: 2007
  end-page: 234
  ident: bib0425
  article-title: Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Li
– volume: 62
  start-page: 755
  year: 2010
  ident: bib0305
  article-title: A systematic review to appraise the quality of cost-effectiveness studies of biologic agents for the treatment of rheumatoid arthritis
  publication-title: Arthritis Rheum
  contributor:
    fullname: Suarez-Almazor
– volume: 36
  start-page: 736
  year: 2009
  end-page: 742
  ident: bib0205
  article-title: Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study
  publication-title: J Rheumatol
  contributor:
    fullname: Li
– volume: 8
  start-page: 76
  year: 2008
  end-page: 82
  ident: bib0060
  article-title: Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept
  publication-title: Autoimmun Rev
  contributor:
    fullname: Campana
– volume: 68
  start-page: 1220
  year: 2009
  end-page: 1227
  ident: bib0090
  article-title: Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Rhodes
– volume: 70
  start-page: 1949
  year: 2011
  end-page: 1956
  ident: bib0195
  article-title: Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Durez
– year: 2007
  ident: bib0025
  article-title: ORENCIA 250
  contributor:
    fullname: Bristol-Myers Squibb Pharma
– volume: 6
  start-page: 15
  year: 2011
  end-page: 24
  ident: bib0175
  article-title: Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis
  publication-title: Int J Clin Rheumatol
  contributor:
    fullname: Genovese
– volume: 31
  start-page: 39
  year: 2011
  end-page: 51
  ident: bib0015
  article-title: Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach
  publication-title: Pharmacotherapy
  contributor:
    fullname: Sullivan
– volume: 39
  start-page: 425
  year: 2010
  end-page: 441
  ident: bib0010
  article-title: Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs
  publication-title: Semin Arthritis Rheum
  contributor:
    fullname: Jansen
– volume: 69
  start-page: 385
  year: 2010
  ident: bib0230
  article-title: Safety, efficacy and health-related quality of life (HRQoL) through 5 years of abatacept (ABA) treatment in patients with rheumatoid arthritis (RA) and an inadequate response to anti-tumour necrosis factor (TNF) therapy
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Aranda
– volume: 68
  start-page: 1819
  year: 2009
  end-page: 1826
  ident: bib0370
  article-title: Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Wolfe
– volume: 68
  start-page: 162
  year: 2010
  end-page: 165
  ident: bib0045
  article-title: T-cell agents in the treatment of rheumatoid arthritis
  publication-title: Bull NYU Hosp Jt Dis
  contributor:
    fullname: Solomon
– volume: 16
  start-page: 332
  year: 2010
  end-page: 334
  ident: bib0350
  article-title: Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection
  publication-title: J Clin Rheumatol
  contributor:
    fullname: Reimold
– volume: 15
  start-page: 1
  year: 2011
  end-page: 300
  ident: bib0295
  article-title: Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
  publication-title: Health Technol Assess
  contributor:
    fullname: Routh
– volume: 68
  start-page: 581
  year: 2009
  ident: bib0120
  article-title: Real World treatment patterns of patients with rheumatoid arthritis receiving two infusible biologics: abatacept and infliximab
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Rosenblatt
– volume: 353
  start-page: 1114
  year: 2005
  end-page: 1123
  ident: bib0160
  article-title: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
  publication-title: N Engl J Med
  contributor:
    fullname: Kremer
– volume: 27
  start-page: 446
  year: 2009
  end-page: 451
  ident: bib0440
  article-title: Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Yazici
– volume: 14
  start-page: 361
  year: 2011
  end-page: 370
  ident: bib0245
  article-title: Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept
  publication-title: Value Health
  contributor:
    fullname: Tugwell
– volume: 69
  start-page: 378
  year: 2010
  ident: bib0290
  article-title: Abatacept therapy is associated with minimal attrition rate irrespective of rheumatoid factor status in patients with highly resistant rheumatoid arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Emery
– year: 2011
  ident: bib0035
  article-title: Oxford centre for evidence-based medicine levels of evidence
  contributor:
    fullname: Haynes
– volume: 31
  start-page: 588
  year: 2011
  end-page: 595
  ident: bib0095
  article-title: CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis
  publication-title: J Clin Immunol
  contributor:
    fullname: Baranda
– volume: 67
  start-page: 1603
  year: 2008
  end-page: 1609
  ident: bib0100
  article-title: CTLA-4 directly inhibits osteoclast formation
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Zwerina
– volume: 49
  start-page: 289
  year: 2010
  end-page: 294
  ident: bib0135
  article-title: Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
  publication-title: Rheumatology (Oxford)
  contributor:
    fullname: Bartoli
– volume: 34
  start-page: 238
  year: 2007
  end-page: 239
  ident: bib0450
  article-title: Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy
  publication-title: J Rheumatol
  contributor:
    fullname: Ostor
– volume: 62
  start-page: 1794
  year: 2010
  ident: bib0270
  article-title: Comparable persistency and effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-naive rheumatoid arthritis patients using the CORRONA registry
  publication-title: Arthritis Rheum
  contributor:
    fullname: Greenberg
– volume: 67
  start-page: 1084
  year: 2008
  end-page: 1089
  ident: bib0185
  article-title: Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Vratsanos
– volume: 69
  start-page: 385
  year: 2010
  ident: bib0255
  article-title: Switching from rituximab to abatacept: tolerance data of 179 patients prospectively followed up in the Orencia and Rheumatoid Arthritis (ORA) registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Legrand
– volume: 68
  start-page: 343
  year: 2009
  ident: bib0280
  article-title: Retrospective analysis of a Canadian rheumatoid arthritis registry: improvement in physical function
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Fanti
– volume: 66
  start-page: 437
  year: 2007
  ident: bib0410
  article-title: Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Bahrt
– volume: 58
  start-page: S786
  year: 2008
  ident: bib0385
  article-title: Autoimmune adverse events in the abatacept ra clinical development program: a safety analysis with 10,000 person-years of exposure
  publication-title: Arthritis Rheum
  contributor:
    fullname: Becker
– volume: 27
  start-page: 907
  year: 2009
  end-page: 913
  ident: bib0110
  article-title: Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Rosenblatt
– volume: 47
  start-page: II48
  year: 2008
  end-page: II50
  ident: bib0215
  article-title: Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate
  publication-title: Rheumatology
  contributor:
    fullname: Aranda
– volume: 71
  start-page: 917
  year: 2008
  end-page: 924
  ident: bib0395
  article-title: CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial
  publication-title: Neurology
  contributor:
    fullname: Hafler
– volume: 5
  start-page: 581
  year: 2010
  end-page: 591
  ident: bib0250
  article-title: Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice
  publication-title: Int J Clin Rheumatol
  contributor:
    fullname: Bars
– volume: 9
  start-page: R38
  year: 2007
  ident: bib0405
  article-title: Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
  publication-title: Arthritis Res Ther
  contributor:
    fullname: Corbo
– volume: 50
  start-page: 437
  year: 2011
  end-page: 449
  ident: bib0225
  article-title: Abatacept treatment for rheumatoid arthritis
  publication-title: Rheumatology (Oxford)
  contributor:
    fullname: Schiff
– volume: 144
  start-page: 865
  year: 2006
  end-page: 876
  ident: bib0150
  article-title: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
  publication-title: Ann Intern Med
  contributor:
    fullname: Abud-Mendoza
– volume: 69
  start-page: 386
  year: 2010
  ident: bib0260
  article-title: Prospective follow-up of abatacept treatment in 920 patients with refractory rheumatoid arthritis: tolerance and efficacy data from the French ORA (Orencia and Rheumatoid Arthritis) registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Combe
– volume: 69
  start-page: 54
  year: 2010
  ident: bib0330
  article-title: Evaluation of the safety profile of abatacept (ABA) by prior therapy in patients with rheumatoid arthritis (RA)
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Aranda
– volume: 70
  start-page: 74
  year: 2011
  ident: bib0285
  article-title: Positivity for RF/ANTI-CCP is associated with a better response to abatacept: data from the Orencia and Rheumatoid Arthritis (ORA) registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Dougados
– volume: 54
  start-page: S248
  year: 2006
  end-page: S249
  ident: bib0320
  article-title: Safety and patient-reported outcomes through 2 years of treatment with abatacept in rheumatoid arthritis patients receiving background disease-modifying antirheumatic drugs (DMARDs): the ASSURE trial
  publication-title: Arthritis Rheum
  contributor:
    fullname: Becker
– volume: 96
  start-page: 987
  year: 1995
  end-page: 993
  ident: bib0085
  article-title: Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig
  publication-title: J Clin Invest
  contributor:
    fullname: Mengle-Gaw
– volume: 97
  start-page: 12711
  year: 2000
  end-page: 12716
  ident: bib0070
  article-title: Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells
  publication-title: Proc Natl Acad Sci USA
  contributor:
    fullname: Allison
– volume: 10
  start-page: R45
  year: 2008
  ident: bib0365
  article-title: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
  publication-title: Arthritis Res Ther
  contributor:
    fullname: Suissa
– volume: 63
  start-page: 2854
  year: 2011
  end-page: 2864
  ident: bib0125
  article-title: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate
  publication-title: Arthritis Rheum
  contributor:
    fullname: Valente
– volume: 56
  start-page: 2557
  year: 2007
  end-page: 2565
  ident: bib0345
  article-title: Abatacept treatment does not exacerbate chronic
  publication-title: Arthritis Rheum
  contributor:
    fullname: Flynn
– volume: 126
  start-page: 38
  year: 2008
  end-page: 47
  ident: bib0075
  article-title: Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction
  publication-title: Clin Immunol
  contributor:
    fullname: Suchard
– volume: 62
  start-page: S768
  year: 2010
  ident: bib0240
  article-title: Sustained and clinically meaningful improvements in both day and night time aspects of HRQoL are observed with abatacept treatment in patients with rheumatoid arthritis and previous inadequate response to MTX: 5-year data from the AIM trial
  publication-title: Arthritis Rheum
  contributor:
    fullname: Emery
– volume: 30
  start-page: 849
  year: 2010
  end-page: 850
  ident: bib0355
  article-title: Abatacept as an option therapy in difficult to treat psoriatic arthritis
  publication-title: Rheumatol Int
  contributor:
    fullname: Vieira
– volume: 62
  start-page: 1792
  year: 2010
  end-page: 1802
  ident: bib0390
  article-title: Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis
  publication-title: Arthritis Rheum
  contributor:
    fullname: Silva
– volume: 70
  start-page: 458
  year: 2011
  ident: bib0420
  article-title: Abatacept in association with traditional DMARDs severely impairs humoral response to pandemic A H1N1 influenza vaccination in rheumatoid arthritis patients
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Aikawa
– volume: 52
  start-page: 2263
  year: 2005
  end-page: 2271
  ident: bib0145
  article-title: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
  publication-title: Arthritis Rheum
  contributor:
    fullname: Shergy
– volume: 104
  start-page: 276
  year: 2009
  end-page: 284
  ident: bib0040
  article-title: Abatacept, a novel CD80/86-CD28T cell co-stimulation modulator, in the treatment of rheumatoid arthritis
  publication-title: Basic Clin Pharmacol Toxicol
  contributor:
    fullname: Moilanen
– volume: 181
  start-page: 787
  year: 2009
  end-page: 796
  ident: bib0005
  article-title: A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
  publication-title: CMAJ
  contributor:
    fullname: Lopez-Olivo
– volume: 204
  start-page: 128
  year: 2005
  end-page: 143
  ident: bib0065
  article-title: The B7/CD28 costimulatory family in autoimmunity
  publication-title: Immunol Rev
  contributor:
    fullname: Sharpe
– volume: 349
  start-page: 1907
  year: 2003
  end-page: 1915
  ident: bib0140
  article-title: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
  publication-title: N Engl J Med
  contributor:
    fullname: Steinfeld
– volume: 69
  start-page: 1768
  year: 2010
  end-page: 1773
  ident: bib0235
  article-title: Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Tugwell
– volume: 70
  start-page: 266
  year: 2011
  end-page: 271
  ident: bib0300
  article-title: Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Bombardier
– volume: 69
  start-page: 675
  year: 2010
  ident: bib0115
  article-title: Infliximab, abatacept and rituximab use in the treatment of rheumatoid arthritis in the real world: view from the infusion unit
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Yazici
– volume: 68
  start-page: 437
  year: 2009
  ident: bib0275
  article-title: Experience with abatacept in a US observational cohort: clinical and patient-reported outcomes from the CORRONA registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Greenberg
– volume: 62
  start-page: S157
  year: 2010
  ident: bib0435
  article-title: Assessment of cardiovascular markers after 24 weeks of abatacept or rituximab therapy in patients with rheumatoid arthritis
  publication-title: Arthritis Rheum
  contributor:
    fullname: Ristori
– volume: 69
  start-page: 541
  year: 2010
  ident: bib0340
  article-title: Serious infections and malignancies during long-term exposure to abatacept
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Aranda
– volume: 76
  start-page: 327
  year: 2009
  end-page: 332
  ident: bib0050
  article-title: Targeting lymphocyte activation to treat rheumatoid arthritis
  publication-title: Joint Bone Spine
  contributor:
    fullname: Boissier
– volume: 68
  start-page: 1708
  year: 2009
  end-page: 1714
  ident: bib0165
  article-title: The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Zhou
– volume: 70
  start-page: i2
  year: 2011
  end-page: i36
  ident: bib0445
  article-title: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
  publication-title: Ann Rheum Dis
  contributor:
    fullname: De Benedetti
– volume: 54
  start-page: 2807
  year: 2006
  end-page: 2816
  ident: bib0315
  article-title: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study
  publication-title: Arthritis Rheum
  contributor:
    fullname: Keystone
– volume: 57
  start-page: A943
  year: 2007
  ident: bib0415
  article-title: Response to influenza vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial
  publication-title: Arthritis Rheum
  contributor:
    fullname: Genovese
– volume: 07
  start-page: 284
  year: 2011
  end-page: 298
  ident: bib0310
  article-title: Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas
  publication-title: Reumatol Clin
  contributor:
    fullname: Cañete
– volume: 68
  start-page: 341
  year: 2009
  ident: bib0210
  article-title: Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naive patients with RA
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Aranda
– volume: 2
  start-page: CD008794
  year: 2011
  ident: bib0020
  article-title: Adverse effects of biologics: a network meta-analysis and Cochrane overview
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Macdonald
– volume: 33
  start-page: 2162
  year: 2006
  end-page: 2166
  ident: bib0080
  article-title: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis
  publication-title: J Rheumatol
  contributor:
    fullname: Nuamah
– volume: 68
  start-page: 1870
  year: 2009
  end-page: 1877
  ident: bib0170
  article-title: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Durez
– volume: 67
  start-page: 1096
  year: 2008
  end-page: 1103
  ident: bib0155
  article-title: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Nayiager
– volume: 36
  start-page: 736
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0205
  article-title: Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.080813
  contributor:
    fullname: Westhovens
– volume: 5
  start-page: 581
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0250
  article-title: Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice
  publication-title: Int J Clin Rheumatol
  doi: 10.2217/ijr.10.52
  contributor:
    fullname: Schiff
– volume: 62
  start-page: 755
  issue: Suppl. 10
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0305
  article-title: A systematic review to appraise the quality of cost-effectiveness studies of biologic agents for the treatment of rheumatoid arthritis
  publication-title: Arthritis Rheum
  contributor:
    fullname: Lopez-Olivo
– volume: 30
  start-page: 849
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0355
  article-title: Abatacept as an option therapy in difficult to treat psoriatic arthritis
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-009-1041-1
  contributor:
    fullname: Vieira
– volume: 68
  start-page: 1819
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0370
  article-title: Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.097527
  contributor:
    fullname: Simon
– volume: 66
  start-page: 228
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0425
  article-title: Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.055111
  contributor:
    fullname: Weinblatt
– volume: 70
  start-page: 266
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0300
  article-title: Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.132134
  contributor:
    fullname: Salliot
– volume: 2
  start-page: CD008794
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0020
  article-title: Adverse effects of biologics: a network meta-analysis and Cochrane overview
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Singh
– volume: 68
  start-page: 1708
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0165
  article-title: The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.099218
  contributor:
    fullname: Schiff
– volume: 16
  start-page: 332
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0350
  article-title: Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection
  publication-title: J Clin Rheumatol
  doi: 10.1097/RHU.0b013e3181f4cd92
  contributor:
    fullname: Mahajan
– volume: 349
  start-page: 1907
  year: 2003
  ident: 10.1016/j.reumae.2012.07.009_bib0140
  article-title: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa035075
  contributor:
    fullname: Kremer
– volume: 50
  start-page: 2297
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0375
  article-title: Non-infectious pulmonary complications of newer biological agents for rheumatic diseases—a systematic literature review
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/ker289
  contributor:
    fullname: Hadjinicolaou
– volume: 69
  start-page: 54
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0330
  article-title: Evaluation of the safety profile of abatacept (ABA) by prior therapy in patients with rheumatoid arthritis (RA)
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Smitten
– volume: 57
  start-page: A943
  issue: Suppl.
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0415
  article-title: Response to influenza vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial
  publication-title: Arthritis Rheum
  contributor:
    fullname: Schiff
– start-page: CD007277
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0030
  article-title: Abatacept for rheumatoid arthritis
  publication-title: Cochrane Database Syst Rev
  contributor:
    fullname: Maxwell
– volume: 204
  start-page: 128
  year: 2005
  ident: 10.1016/j.reumae.2012.07.009_bib0065
  article-title: The B7/CD28 costimulatory family in autoimmunity
  publication-title: Immunol Rev
  doi: 10.1111/j.0105-2896.2005.00242.x
  contributor:
    fullname: Keir
– volume: 70
  start-page: 1826
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0200
  article-title: Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.139345
  contributor:
    fullname: Kremer
– volume: 96
  start-page: 987
  year: 1995
  ident: 10.1016/j.reumae.2012.07.009_bib0085
  article-title: Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig
  publication-title: J Clin Invest
  doi: 10.1172/JCI118146
  contributor:
    fullname: Knoerzer
– volume: 58
  start-page: S786
  issue: Suppl. 9
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0385
  article-title: Autoimmune adverse events in the abatacept ra clinical development program: a safety analysis with 10,000 person-years of exposure
  publication-title: Arthritis Rheum
  contributor:
    fullname: Smitten
– volume: 6
  start-page: 15
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0175
  article-title: Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis
  publication-title: Int J Clin Rheumatol
  doi: 10.2217/ijr.11.1
  contributor:
    fullname: Peterfy
– volume: 31
  start-page: 39
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0015
  article-title: Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach
  publication-title: Pharmacotherapy
  doi: 10.1592/phco.31.1.39
  contributor:
    fullname: Devine
– volume: 69
  start-page: 385
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0255
  article-title: Switching from rituximab to abatacept: tolerance data of 179 patients prospectively followed up in the Orencia and Rheumatoid Arthritis (ORA) registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Gottenberg
– volume: 181
  start-page: 787
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0005
  article-title: A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
  publication-title: CMAJ
  doi: 10.1503/cmaj.091391
  contributor:
    fullname: Singh
– volume: 15
  start-page: 1
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0295
  article-title: Adalimumab, etanercept, infiximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
  publication-title: Health Technol Assess
  doi: 10.3310/hta15140
  contributor:
    fullname: Malottki
– volume: 62
  start-page: S157
  issue: Suppl.
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0435
  article-title: Assessment of cardiovascular markers after 24 weeks of abatacept or rituximab therapy in patients with rheumatoid arthritis
  publication-title: Arthritis Rheum
  contributor:
    fullname: Mathieu
– volume: 68
  start-page: 440
  issue: Suppl. 3
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0455
  article-title: Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Genant
– volume: 70
  start-page: i2
  issue: Suppl. 1
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0445
  article-title: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.146852
  contributor:
    fullname: Furst
– volume: 62
  start-page: S164
  issue: Suppl.
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0400
  article-title: Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment
  publication-title: Arthritis Rheum
  contributor:
    fullname: Hochberg
– year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0025
  contributor:
    fullname: Bristol-Myers Squibb Pharma
– volume: 69
  start-page: 541
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0340
  article-title: Serious infections and malignancies during long-term exposure to abatacept
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Smitten
– volume: 27
  start-page: 446
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0440
  article-title: Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Schimmel
– volume: 70
  start-page: 74
  issue: Suppl. 3
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0285
  article-title: Positivity for RF/ANTI-CCP is associated with a better response to abatacept: data from the Orencia and Rheumatoid Arthritis (ORA) registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Gottenberg
– volume: 68
  start-page: 437
  issue: Suppl. 3
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0275
  article-title: Experience with abatacept in a US observational cohort: clinical and patient-reported outcomes from the CORRONA registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Gibofsky
– volume: 69
  start-page: 378
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0290
  article-title: Abatacept therapy is associated with minimal attrition rate irrespective of rheumatoid factor status in patients with highly resistant rheumatoid arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Buch
– volume: 76
  start-page: 327
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0050
  article-title: Targeting lymphocyte activation to treat rheumatoid arthritis
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2008.12.007
  contributor:
    fullname: Falgarone
– volume: 67
  start-page: 1096
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0155
  article-title: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2007.080002
  contributor:
    fullname: Schiff
– volume: 97
  start-page: 12711
  year: 2000
  ident: 10.1016/j.reumae.2012.07.009_bib0070
  article-title: Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.220423597
  contributor:
    fullname: Kuhns
– volume: 126
  start-page: 38
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0075
  article-title: Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2007.08.019
  contributor:
    fullname: Davis
– volume: 27
  start-page: 510
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0055
  article-title: Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Choy
– volume: 104
  start-page: 276
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0040
  article-title: Abatacept, a novel CD80/86-CD28T cell co-stimulation modulator, in the treatment of rheumatoid arthritis
  publication-title: Basic Clin Pharmacol Toxicol
  doi: 10.1111/j.1742-7843.2009.00375.x
  contributor:
    fullname: Korhonen
– volume: 68
  start-page: 343
  issue: Suppl. 3
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0280
  article-title: Retrospective analysis of a Canadian rheumatoid arthritis registry: improvement in physical function
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Donato
– volume: 16
  start-page: 69
  issue: Suppl. 1
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0380
  article-title: Pulmonary toxicity of biological anti-inflammatory agents—a systematic review
  publication-title: Respirology
  contributor:
    fullname: Rao
– volume: 34
  start-page: 238
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0450
  article-title: Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy
  publication-title: J Rheumatol
  contributor:
    fullname: Roos
– volume: 63
  start-page: 2854
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0125
  article-title: Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate
  publication-title: Arthritis Rheum
  doi: 10.1002/art.30463
  contributor:
    fullname: Genovese
– volume: 27
  start-page: 907
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0110
  article-title: Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Yazici
– volume: 353
  start-page: 1114
  year: 2005
  ident: 10.1016/j.reumae.2012.07.009_bib0160
  article-title: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050524
  contributor:
    fullname: Genovese
– volume: 68
  start-page: 1870
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0170
  article-title: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.101121
  contributor:
    fullname: Westhovens
– volume: 70
  start-page: 1949
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0195
  article-title: Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.145268
  contributor:
    fullname: Bathon
– volume: 9
  start-page: R38
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0405
  article-title: Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2174
  contributor:
    fullname: Tay
– volume: 10
  start-page: R45
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0365
  article-title: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2404
  contributor:
    fullname: Smitten
– volume: 21
  start-page: 231
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0180
  article-title: Recent concepts in the inhibition of radiographic progression with biologics
  publication-title: Curr Opin Rheumatol
  doi: 10.1097/BOR.0b013e328329f84f
  contributor:
    fullname: Keystone
– volume: 50
  start-page: 437
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0225
  article-title: Abatacept treatment for rheumatoid arthritis
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keq287
  contributor:
    fullname: Schiff
– volume: 69
  start-page: 675
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0115
  article-title: Infliximab, abatacept and rituximab use in the treatment of rheumatoid arthritis in the real world: view from the infusion unit
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Kushnir
– volume: 69
  start-page: 200
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0360
  article-title: Biological agents in inactive HBsAg carriers with inflammatory arthritis: a role of prophylactic antiviral treatment
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Zisopoulos
– volume: 69
  start-page: 1768
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0235
  article-title: Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2009.119727
  contributor:
    fullname: Wells
– volume: 14
  start-page: 361
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0245
  article-title: Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept
  publication-title: Value Health
  doi: 10.1016/j.jval.2010.10.008
  contributor:
    fullname: Li
– volume: 69
  start-page: 386
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0260
  article-title: Prospective follow-up of abatacept treatment in 920 patients with refractory rheumatoid arthritis: tolerance and efficacy data from the French ORA (Orencia and Rheumatoid Arthritis) registry
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Gottenberg
– volume: 144
  start-page: 865
  year: 2006
  ident: 10.1016/j.reumae.2012.07.009_bib0150
  article-title: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-144-12-200606200-00003
  contributor:
    fullname: Kremer
– volume: 71
  start-page: 917
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0395
  article-title: CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000325915.00112.61
  contributor:
    fullname: Viglietta
– volume: 29
  start-page: 583
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0220
  article-title: Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-009-1363-0
  contributor:
    fullname: Schiff
– volume: 62
  start-page: 1794
  issue: Suppl. 10
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0270
  article-title: Comparable persistency and effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-naive rheumatoid arthritis patients using the CORRONA registry
  publication-title: Arthritis Rheum
  contributor:
    fullname: Harrold
– volume: 67
  start-page: 338
  issue: Suppl. II
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0335
  article-title: Descriptive analysis of serious infections, hospitalized infections and malignancies over time in the abatacept clinical development program: a safety update with 10,000 person-years of exposure
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Smitten
– volume: 68
  start-page: 1220
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0090
  article-title: Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2008.091876
  contributor:
    fullname: Buch
– volume: 12
  start-page: R67
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0325
  article-title: Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar2984
  contributor:
    fullname: Simon
– volume: 70
  start-page: 2003
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0190
  article-title: Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200316
  contributor:
    fullname: Schiff
– volume: 68
  start-page: 341
  issue: Suppl. III
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0210
  article-title: Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naive patients with RA
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Westhovens
– volume: 62
  start-page: 1792
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0390
  article-title: Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.27431
  contributor:
    fullname: Ruperto
– volume: 70
  start-page: 458
  issue: Suppl. 3
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0420
  article-title: Abatacept in association with traditional DMARDs severely impairs humoral response to pandemic A H1N1 influenza vaccination in rheumatoid arthritis patients
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Ribeiro
– volume: 69
  start-page: 388
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0430
  article-title: Assessment of arterial stiffness after 24 weeks of abatacept therapy in 17 patients with rheumatoid arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Mathieu
– volume: 33
  start-page: 2162
  year: 2006
  ident: 10.1016/j.reumae.2012.07.009_bib0080
  article-title: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis
  publication-title: J Rheumatol
  contributor:
    fullname: Weisman
– volume: 52
  start-page: 2263
  year: 2005
  ident: 10.1016/j.reumae.2012.07.009_bib0145
  article-title: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
  publication-title: Arthritis Rheum
  doi: 10.1002/art.21201
  contributor:
    fullname: Kremer
– volume: 54
  start-page: 2807
  year: 2006
  ident: 10.1016/j.reumae.2012.07.009_bib0315
  article-title: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22070
  contributor:
    fullname: Weinblatt
– volume: 8
  start-page: 76
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0060
  article-title: Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2008.07.035
  contributor:
    fullname: Fiocco
– volume: 68
  start-page: 162
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0045
  article-title: T-cell agents in the treatment of rheumatoid arthritis
  publication-title: Bull NYU Hosp Jt Dis
  contributor:
    fullname: Solomon
– volume: 34
  start-page: 2204
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0105
  article-title: Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity
  publication-title: J Rheumatol
  contributor:
    fullname: Davis
– volume: 56
  start-page: 2557
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0345
  article-title: Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22750
  contributor:
    fullname: Bigbee
– year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0035
  contributor:
    fullname: Phillips
– volume: 69
  start-page: 385
  issue: Suppl. 3
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0230
  article-title: Safety, efficacy and health-related quality of life (HRQoL) through 5 years of abatacept (ABA) treatment in patients with rheumatoid arthritis (RA) and an inadequate response to anti-tumour necrosis factor (TNF) therapy
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Genovese
– volume: 68
  start-page: 581
  issue: Suppl. 3
  year: 2009
  ident: 10.1016/j.reumae.2012.07.009_bib0120
  article-title: Real World treatment patterns of patients with rheumatoid arthritis receiving two infusible biologics: abatacept and infliximab
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Simons
– volume: 47
  start-page: II48
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0215
  article-title: Long-term efficacy and safety of abatacept through 5 years of treatment in rheumatoid arthritis patients with an inadequate response to methotrexate
  publication-title: Rheumatology
  contributor:
    fullname: Emery
– volume: 70
  start-page: 1216
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0265
  article-title: Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.140129
  contributor:
    fullname: Leffers
– volume: 31
  start-page: 588
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0095
  article-title: CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis
  publication-title: J Clin Immunol
  doi: 10.1007/s10875-011-9527-5
  contributor:
    fullname: Alvarez-Quiroga
– volume: 67
  start-page: 1603
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0100
  article-title: CTLA-4 directly inhibits osteoclast formation
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2007.080713
  contributor:
    fullname: Axmann
– volume: 62
  start-page: S768
  issue: Suppl.
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0240
  article-title: Sustained and clinically meaningful improvements in both day and night time aspects of HRQoL are observed with abatacept treatment in patients with rheumatoid arthritis and previous inadequate response to MTX: 5-year data from the AIM trial
  publication-title: Arthritis Rheum
  contributor:
    fullname: Kremer
– volume: 39
  start-page: 425
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0010
  article-title: Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2009.12.002
  contributor:
    fullname: Bergman
– volume: 49
  start-page: 289
  year: 2010
  ident: 10.1016/j.reumae.2012.07.009_bib0135
  article-title: Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/kep354
  contributor:
    fullname: Scarpato
– volume: 67
  start-page: 1084
  year: 2008
  ident: 10.1016/j.reumae.2012.07.009_bib0185
  article-title: Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2007.085084
  contributor:
    fullname: Genant
– volume: 66
  start-page: 437
  issue: Suppl. II
  year: 2007
  ident: 10.1016/j.reumae.2012.07.009_bib0410
  article-title: Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Schiff
– volume: 54
  start-page: S248
  year: 2006
  ident: 10.1016/j.reumae.2012.07.009_bib0320
  article-title: Safety and patient-reported outcomes through 2 years of treatment with abatacept in rheumatoid arthritis patients receiving background disease-modifying antirheumatic drugs (DMARDs): the ASSURE trial
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22070
  contributor:
    fullname: Weinblatt
– volume: 71
  start-page: 38
  year: 2012
  ident: 10.1016/j.reumae.2012.07.009_bib0130
  article-title: Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-200344
  contributor:
    fullname: Kaine
– volume: 07
  start-page: 284
  year: 2011
  ident: 10.1016/j.reumae.2012.07.009_bib0310
  article-title: Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas
  publication-title: Reumatol Clin
  doi: 10.1016/j.reuma.2011.05.002
  contributor:
    fullname: Gómez-Reino
SSID ssj0000825967
Score 1.8706274
Snippet To review the clinical evidence on abatacept and to formulate recommendations in order to clear up points related to its use in rheumatology. An expert panel...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 5
SubjectTerms Abatacept
CTLA-4-Ig
Evidence-based practice
Práctica basada en evidencias
Title Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations
URI https://dx.doi.org/10.1016/j.reumae.2012.07.009
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Li9swEBbZLZReSp90-0KH3hYH-Sm7t92uy1LaHvIoSy9GsiQ2IXHKZnPpr--MJCtpE0pb6MUYoYeZ-Rh9Gs-MCHlTpgoOCcZEzJQiyvJSRyKR8CY17EaZTkWL-c6XY_75qryos3owCFUXQtt_1TS0ga4xc_YvtB0mhQZ4B53DE7QOzz_S-5kUtwJjVU6na1sQZHStN0BLVzOFnvhrW8QI_QD9faJ9bX2XqQiftNT-oqX1LnMduVnAVNp_6xchqRI56jlmTC5WmF8WHAtYoMB17cByLCxJrZezhQv8ct7TxVr4LJu5wMoJB8bq76cTAKpQtucX19q6GsnONyS6ZehuESNmSw82787AqyV-cmeEPJsaDCqOPI_t9OPhx-F0axvhIJVGOXcVnob6QJs37tUehp2hznd2fJc8ureXOLfGfHiD8sWKqug2xoKX1XbvDBGNY1wdF48T-zf_6ojcScD2oen9mo-C2w9P5JW91zh8bp_QaaMO9xc7TJh2SNDkAbnvTy_0zMHuIRno7hG5-8nHZzwmHwL6KKCPzjq6RR8N6HtLe-xRhz0Kyqe_YO8Jmb6vJ-8uI39bR9QmeHuRzLisCsPj2GSsankhYqC7plASTrTAG03FhRSZKHlZwBm7FWAcmEmZAE6sWW7Sp-S4W3X6GaFppViimFQyR8LJBZBcnbWtyooWJMxOSNSLpPnmirI0fbTivHEibFCEDcPoiuqE8F5ujSeWjjA2oOvfjnz-zyNfkHtbeL8kx7c3G_2KHK3V5rVFxA_NnZbB
link.rule.ids 315,782,786,27933,27934
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abatacept+Use+in+Rheumatoid+Arthritis%3A+Evidence+Review+and+Recommendations&rft.jtitle=Reumatolog%C3%ADa+clinica+%28Barcelona%29&rft.au=Mart%C3%ADn+Mola%2C+Emilio&rft.au=Balsa%2C+Alejandro&rft.au=Mart%C3%ADnez+Taboada%2C+V%C3%ADctor&rft.au=Sanmart%C3%AD%2C+Raimon&rft.date=2013-01-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=2173-5743&rft.eissn=2173-5743&rft.volume=9&rft.issue=1&rft.spage=5&rft.epage=17&rft_id=info:doi/10.1016%2Fj.reumae.2012.07.009&rft.externalDocID=S217357431200127X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2173-5743&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2173-5743&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2173-5743&client=summon